Purple Biotech Ltd. Sponsored ADR

Description

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.